TY - JOUR
T1 - Microhomology-assisted scarless genome editing in human iPSCs
AU - Kim, Shin Il
AU - Matsumoto, Tomoko
AU - Kagawa, Harunobu
AU - Nakamura, Michiko
AU - Hirohata, Ryoko
AU - Ueno, Ayano
AU - Ohishi, Maki
AU - Sakuma, Tetsushi
AU - Soga, Tomoyoshi
AU - Yamamoto, Takashi
AU - Woltjen, Knut
N1 - Funding Information:
We would like to acknowledge the technical assistance of Kikumi Horiguchi for initial TALEN evaluation and genotyping, Chiho Sakurai for cell culture support, and Kanae Mitsunaga for FACS. Norikazu Saiki and Megumu Saito provided advice in setting up iPSC metabolomics. We thank Koichi Kawakami for provision of the CAG promoter, as well as Rudolf Jaenisch, Daniel Voytas, and Feng Zhang for provision of reagents through Addgene. This work was funded in part by grants to K.W. from the Japan Society for the Promotion of Science (Wakate B), the Kyoto University Hakubi Project, and the Research Center Network for Realization of Regenerative Medicine, Program for Intractable Diseases Research Utilizing Disease-Specific iPS Cells, of the Japan Agency for Medical Research and Development (AMED). K.W. is a Hakubi Center Special Project Researcher.
Publisher Copyright:
© 2018 The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Gene-edited induced pluripotent stem cells (iPSCs) provide relevant isogenic human disease models in patient-specific or healthy genetic backgrounds. Towards this end, gene targeting using antibiotic selection along with engineered point mutations remains a reliable method to enrich edited cells. Nevertheless, integrated selection markers obstruct scarless transgene-free gene editing. Here, we present a method for scarless selection marker excision using engineered microhomology-mediated end joining (MMEJ). By overlapping the homology arms of standard donor vectors, short tandem microhomologies are generated flanking the selection marker. Unique CRISPR-Cas9 protospacer sequences nested between the selection marker and engineered microhomologies are cleaved after gene targeting, engaging MMEJ and scarless excision. Moreover, when point mutations are positioned unilaterally within engineered microhomologies, both mutant and normal isogenic clones are derived simultaneously. The utility and fidelity of our method is demonstrated in human iPSCs by editing the X-linked HPRT1 locus and biallelic modification of the autosomal APRT locus, eliciting disease-relevant metabolic phenotypes.
AB - Gene-edited induced pluripotent stem cells (iPSCs) provide relevant isogenic human disease models in patient-specific or healthy genetic backgrounds. Towards this end, gene targeting using antibiotic selection along with engineered point mutations remains a reliable method to enrich edited cells. Nevertheless, integrated selection markers obstruct scarless transgene-free gene editing. Here, we present a method for scarless selection marker excision using engineered microhomology-mediated end joining (MMEJ). By overlapping the homology arms of standard donor vectors, short tandem microhomologies are generated flanking the selection marker. Unique CRISPR-Cas9 protospacer sequences nested between the selection marker and engineered microhomologies are cleaved after gene targeting, engaging MMEJ and scarless excision. Moreover, when point mutations are positioned unilaterally within engineered microhomologies, both mutant and normal isogenic clones are derived simultaneously. The utility and fidelity of our method is demonstrated in human iPSCs by editing the X-linked HPRT1 locus and biallelic modification of the autosomal APRT locus, eliciting disease-relevant metabolic phenotypes.
UR - http://www.scopus.com/inward/record.url?scp=85042920744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042920744&partnerID=8YFLogxK
U2 - 10.1038/s41467-018-03044-y
DO - 10.1038/s41467-018-03044-y
M3 - Article
C2 - 29507284
AN - SCOPUS:85042920744
SN - 2041-1723
VL - 9
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 939
ER -